Volume 20, Issue 6
June 2018
Cover image
Cover image
The cover image is Fig. 1 from “Molecular subtyping of tumors from patients with familial glioma” by Ruiz and Praska et al. pp. 810-817.
ISSN 1522-8517
EISSN 1523-5866
Issue navigation
Volume 20, Issue 6, June 2018
Editorials
How should adult patients with neurofibromatosis 1 be managed?
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 721–722, https://doi.org/10.1093/neuonc/noy050
Platform trials arrive on time for glioblastoma
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 723–725, https://doi.org/10.1093/neuonc/noy040
Highlights from the Literature
Highlights from the Literature
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 726–728, https://doi.org/10.1093/neuonc/noy062
Reviews
Recent advances in intradural spinal tumors
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 729–742, https://doi.org/10.1093/neuonc/nox230
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 743–752, https://doi.org/10.1093/neuonc/nox191
Basic and Translational Investigations
PRMT5 as a druggable target for glioblastoma therapy
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 753–763, https://doi.org/10.1093/neuonc/nox206
A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 764–775, https://doi.org/10.1093/neuonc/nox215
An NF-κB signature predicts low-grade glioma prognosis: a precision medicine approach based on patient-derived stem cells
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 776–787, https://doi.org/10.1093/neuonc/nox234
Altered brain morphology after focal radiation reveals impact of off-target effects: implications for white matter development and neurogenesis
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 788–798, https://doi.org/10.1093/neuonc/nox211
Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 799–809, https://doi.org/10.1093/neuonc/nox241
Molecular subtyping of tumors from patients with familial glioma
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 810–817, https://doi.org/10.1093/neuonc/nox192
Clinical Investigations
The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 818–825, https://doi.org/10.1093/neuonc/noy013
Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation—the NCT Neuro Master Match (N2M2) pilot study
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 826–837, https://doi.org/10.1093/neuonc/nox216
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 838–847, https://doi.org/10.1093/neuonc/nox202
Neuroimaging
Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 848–857, https://doi.org/10.1093/neuonc/nox188
Letters to the Editor
β–III-spectrin immunohistochemistry as a potential diagnostic tool with high sensitivity for malignant peripheral nerve sheath tumors
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 858–860, https://doi.org/10.1093/neuonc/noy038
Survival of patients with prior anti-angiogenic therapy
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 860–861, https://doi.org/10.1093/neuonc/noy039
Muscular disorder related to immune checkpoint inhibitors: forewarned is forearmed
Neuro-Oncology, Volume 20, Issue 6, June 2018, Pages 861–862, https://doi.org/10.1093/neuonc/noy031
Society News
Forthcoming Meetings
Neuro-Oncology, Volume 20, Issue 6, June 2018, Page 863, https://doi.org/10.1093/neuonc/noy061
